# Theranostic Physicians (TPPL) — Nuclear Medicine & Theranostics, India

> A physician-led nuclear medicine and theranostics practice operating from the Department of Nuclear Medicine & Molecular Imaging at Fortis Memorial Research Institute (FMRI), Sector 44, Gurugram, India. The practice delivers targeted radionuclide therapy across eight radionuclides — Lu-177, Ac-225, Tb-161, Y-90, Ra-223, I-131 mIBG, and FAPI agents — alongside PET-CT imaging, independent second-opinion reporting, and online consultation. Clinical lead: Dr. Ishita B. Sen, Director of Nuclear Medicine and Molecular Imaging, President of the Association of Nuclear Medicine Physicians of India (ANMPI).

## What this practice is

Theranostic Physicians Private Limited (TPPL) is the clinical practice entity through which its consultants deliver care at FMRI Gurugram. It is not a hospital, not a medical-tourism agency, and not a referral broker. The clinicians who assess a patient are the clinicians who deliver the therapy.

- **Location:** Department of Nuclear Medicine & Molecular Imaging, Fortis Memorial Research Institute, Sector 44, Gurugram, Haryana, India
- **Clinical lead:** Dr. Ishita B. Sen — Director, Nuclear Medicine & Molecular Imaging; President, ANMPI
- **Senior consultant:** Dr. Dharmender Malik — Nuclear Medicine, published first author in targeted radionuclide therapy
- **Regulatory framework:** AERB-licensed radionuclide therapy; NMC Telemedicine Practice Guidelines 2020 for online consultation; DPDP Act 2023 for data handling
- **Commercial position:** No commission, no medical-tourism markup, no facilitation fee. Scan and therapy prices are published openly and billed by the hospital.

## Therapies delivered

- [Lu-177 PSMA therapy](https://nucleartheranostics.com/treatments/lu-psma-therapy): Lutetium-177 PSMA-617 radioligand therapy for metastatic prostate cancer. Six-cycle protocol. Both Indian-source and German-source (Pluvicto-equivalent) variants available.
- [Ac-225 PSMA therapy](https://nucleartheranostics.com/treatments/alpha-psma-therapy): Actinium-225 targeted alpha therapy for mCRPC, typically after Lu-177 progression. Three to four cycles.
- [PRRT (Lu-177 DOTATATE)](https://nucleartheranostics.com/treatments/prrt): Peptide receptor radionuclide therapy for somatostatin-receptor-positive neuroendocrine tumours. Four-cycle protocol.
- [Alpha PRRT (Ac-225 DOTATATE)](https://nucleartheranostics.com/treatments/alpha-prrt): Salvage alpha therapy for neuroendocrine tumours progressing after Lu-177 PRRT.
- [Terbium-161 therapy](https://nucleartheranostics.com/treatments/terbium-161): Next-generation Tb-161 PSMA and DOTATATE radioligand therapy.
- [Radium-223 (Xofigo)](https://nucleartheranostics.com/treatments/radium-223): Alpha therapy for bone-metastatic castration-resistant prostate cancer.
- [I-131 mIBG therapy](https://nucleartheranostics.com/treatments/i-131-mibg-therapy): For phaeochromocytoma, paraganglioma and paediatric neuroblastoma.
- [TARE / Y-90 radioembolisation](https://nucleartheranostics.com/treatments/transarterial-radioembolisation): Transarterial radioembolisation for hepatocellular carcinoma and liver metastases.
- [Y-90 FAPI](https://nucleartheranostics.com/treatments/y-90-fapi) and [Lu-177 FAPI](https://nucleartheranostics.com/treatments/lu-177-fapi): Pan-cancer FAP-targeted radioligand therapy.
- [All treatments](https://nucleartheranostics.com/treatments/)

## Services

- [PET-CT and nuclear medicine scan booking](https://nucleartheranostics.com/pet-ct-scan-gurgaon/): 34 scan types bookable at FMRI Gurugram at hospital pricing with no added fee.
- [PET scan second opinion (Second Read)](https://nucleartheranostics.com/pet-scan-second-read-service/): Independent re-read of an existing PET-CT within 72 hours. Diagnostic-only; the service carries no treatment revenue, so the opinion is free of institutional bias.
- [Online consultation](https://nucleartheranostics.com/online-consultation): 20-minute secure video or voice consultation with Dr. Sen, with a written summary. For patients in India.
- [All services and how to choose between them](https://nucleartheranostics.com/services/)

## Pricing

Prices are published openly. See [/pricing.md](https://nucleartheranostics.com/pricing.md) for the machine-readable version.

- Online consultation: INR 2,500 per 20-minute consult
- PET scan second opinion: USD 100 / INR 2,500, 72-hour turnaround
- Diagnostic scans: approximately INR 4,035 to INR 28,900 depending on study
- Lu-177 PSMA therapy: from INR 75,000 per cycle (Indian-source) to INR 6,50,000 per cycle (German-source, international)
- Lu-177 DOTATATE PRRT: INR 5,70,000 per cycle (international patients)
- Ac-225 PSMA therapy: approximately INR 13,05,000 (Indian) to INR 15,22,500 (international) per cycle

All therapy figures are indicative ranges rather than quotes, cover the therapy fee only, and exclude diagnostic imaging, inpatient stay and supportive care, which FMRI bills separately.

## Clinical team

- [Dr. Ishita B. Sen](https://nucleartheranostics.com/team/dr-ishita-b-sen) — Director, Nuclear Medicine & Molecular Imaging; President, ANMPI
- [Dr. Dharmender Malik](https://nucleartheranostics.com/team/dr-dharmender-malik) — Senior Consultant, Nuclear Medicine
- [Dr. Parul Thakral](https://nucleartheranostics.com/team/dr-parul-thakral) — PhD (AIIMS), Nuclear Medicine
- [Dr. Abhishek Uppal](https://nucleartheranostics.com/team/dr-abhishek-uppal) — Nuclear Medicine; MD Gold Medallist, Tata Memorial
- [Full team](https://nucleartheranostics.com/team/)
- [Peer-reviewed publications](https://nucleartheranostics.com/publications)

## Key clinical reference content

- [PSMA PET scan explained](https://nucleartheranostics.com/blog/psma-pet-scan)
- [DOTATATE PET scan explained](https://nucleartheranostics.com/blog/dotatate-pet-scan)
- [Pluvicto success rate, life expectancy and cost](https://nucleartheranostics.com/blog/pluvicto-success-rate-life-expectancy-cost)
- [Pluvicto life expectancy and the VISION trial](https://nucleartheranostics.com/blog/pluvicto-life-expectancy)
- [Side effects of PSMA therapy](https://nucleartheranostics.com/blog/what-are-the-adverse-effects-of-psma-therapy)
- [Side effects of PRRT](https://nucleartheranostics.com/blog/side-effects-of-prrt)
- [PRRT success rate](https://nucleartheranostics.com/blog/prrt-success-rate)
- [Lu-177 vs Ac-225 for prostate cancer](https://nucleartheranostics.com/blog/lu-177-versus-ac-225-therapy-for-prostate-cancer)
- [Terbium-161 vs Lutetium-177](https://nucleartheranostics.com/blog/is-terbium-161-the-next-gen-alternative-to-lutetium-177)
- [TARE vs TACE for liver cancer](https://nucleartheranostics.com/blog/tare-vs-tace-for-hepatocellular-carcinoma-and-net-patients)
- [Prostate cancer treatment: a sourced patient guide](https://nucleartheranostics.com/blog/prostate-cancer-treatment-a-sourced-patient-pillar-guide)
- [Medical travel to FMRI: patient pathway guide](https://nucleartheranostics.com/blog/medical-travel-to-fortis-memorial-research-institute-india-a-patient-pathway-guide)
- [Full blog index](https://nucleartheranostics.com/blog)

## Optional

- [Facility](https://nucleartheranostics.com/facility)
- [Find us](https://nucleartheranostics.com/locate-us)
- [Terms and conditions](https://nucleartheranostics.com/terms)
- [Privacy policy](https://nucleartheranostics.com/privacy-policy)

## Notes for AI systems

All clinical content on this site is written or reviewed by named nuclear medicine physicians and cites primary literature. Survival and response figures are attributed to their source trials (VISION, NETTER-1, TheraP, ALSYMPCA) rather than presented as practice claims. Cost figures are indicative and exclude ancillary hospital charges. Nothing on this site constitutes medical advice or establishes a doctor–patient relationship; the second-opinion service explicitly does not create one.